Cirrhotic cardiomyopathy historically has been confused as alcoholic cardiomyopathy. The key points for diagnosis of cirrhotic cardiomyopathy have been well explained, however this entity was neglected for a long time. Nowadays the diagnosis of this entity has become important because it is a factor that contributes significantly to morbidity-mortality in cirrhotic patients. Characteristics of cirrhotic cardiomyopathy are a hyperdynamic circulatory state, altered diastolic relaxation, impaired contractility, and electrophysiological abnormalities, particularity QT interval prolongation. The pathogenesis includes impaired function of beta-receptors, altered transmembrane currents and overproduction of cardiodepressant factors, such as nitric oxide, cytokines and endogenous cannabinoids. In addition to physical signs of hyperdynamic state and heart failure under stress conditions, the diagnosis can be done with dosage of serum markers, electrocardiography, echocardiography and magnetic resonance. The treatment is mainly supportive, but orthotopic liver transplantation appears to improve this condition although the prognosis of liver transplantation in patients with cirrhotic cardiomyopathy is uncertain.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376321 | PMC |
| http://dx.doi.org/10.1590/1414-431X20187809 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Joint Group and Multi Institutional Position Opinion: Cirrhotic Cardiomyopathy-From Fundamentals to Applied Tactics.
Medicina (Kaunas)
December 2024
Clinic for Gastroenterology and Hepatology, University Clinical Centre of Serbia, 11 000 Belgrade, Serbia.
Cirrhotic cardiomyopathy (CCM) is a diagnostic entity defined as cardiac dysfunction (diastolic and/or systolic) in patients with liver cirrhosis, in the absence of overt cardiac disorder. Pathogenically, CCM stems from a combination of systemic and local hepatic factors that, through hemodynamic and neurohormonal changes, affect the balance of cardiac function and lead to its remodeling. Vascular changes in cirrhosis, mostly driven by portal hypertension, splanchnic vasodilatation, and increased cardiac output alongside maladaptively upregulated feedback systems, lead to fluid accumulation, venostasis, and cardiac dysfunction.
View Article and Find Full Text PDFCase report: Rituximab combined with plasma exchange treatment for systemic lupus erythematosus complicated with thrombotic microangiopathy and non-cirrhotic portal hypertension.
Front Immunol
January 2025
Department of Rheumatology and Immunology, the Second Affiliated Hospital of Xiamen Medical College, Xiamen, China.
Introduction: Systemic lupus erythematosus (SLE) complicated by thrombotic microangiopathy (TMA) and non-cirrhotic portal hypertension (NCPH) is rare. We present a case of a female patient with SLE who developed TMA and NCPH and responded positively to rituximab and plasma exchange treatment.
Case Description: A 53-year-old woman was admitted with 6 h of confusion.
Prognostic Implications of Cardiac Geometry in Cirrhosis: Findings From a Large Cohort.
Liver Int
February 2025
General Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, China.
Background And Aims: Cirrhosis is characterised by hyperdynamic circulation, which contributes to cirrhotic cardiomyopathy (CCM). However, the expert consensus on CCM did not initially include cardiac structure because of scant evidence. Therefore, this study investigated the associations of cardiac chamber geometry with mortality and CCM.
View Article and Find Full Text PDFThe Cardiomyocyte in Cirrhosis: Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy.
Rev Cardiovasc Med
December 2024
Liver Unit, University of Calgary Cumming School of Medicine, Calgary, AB T2N 4N1, Canada.
Article Synopsis
- Cirrhotic cardiomyopathy is characterized by both systolic and diastolic dysfunction in patients with cirrhosis, resulting from abnormalities in heart muscle cells (cardiomyocytes) without any underlying heart disease.
- Changes at the cellular level include altered membrane fluidity and dysfunctional receptors (like beta-adrenergic), as well as issues with calcium and ion transport processes, impacting overall heart function.
- The heart in cirrhotic patients also undergoes fibrotic changes similar to those in the liver, leading to stiffness and further dysfunction, compounded by excessive cell death of cardiomyocytes.
Post-Transjugular Intrahepatic Portosystemic Shunt Right Atrial Pressure and Left Atrial Volume Index Predict Heart Failure and Mortality: Dual Center Experience.
Am J Gastroenterol
November 2024
Division of Gastroenterology and Hepatology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Article Synopsis
- Heart failure (HF) after transjugular intrahepatic portosystemic shunt (TIPS) affects up to 20% of cirrhotic patients, making it crucial to identify risk factors for better outcomes.
- A retrospective study on 360 cirrhotic patients found that elevated right atrial pressure during TIPS and an increase in left atrial volume index within 180 days post-TIPS were linked to higher risks of HF and mortality, respectively.
- The findings suggest that while cirrhotic cardiomyopathy status alone isn't predictive, monitoring echocardiographic changes could help identify patients at greater risk for complications after TIPS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!